Stocks
Apogee Therapeutics IncAPGE
NASDAQHealthcareBiotechnology$135.07
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing antibody therapies for inflammatory and immunologic diseases, including asthma and chronic obstructive pulmonary disease. Its lead candidates target IL-13 and OX40L pathways, positioning it among a group of companies racing to improve on existing biologic treatments. Investors track Apogee for its early-stage pipeline and upcoming clinical data readouts.
52W Range: $35.39-$135.09
Congressional Interest in Apogee Therapeutics Inc (APGE)
No congressional trades have been disclosed for Apogee Therapeutics Inc (APGE) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading APGE?
No congressional trades found for this stock.